Cosentyx Gains FDA Approval for Scalp Psoriasis

Cosentyx gets FDA approval

The FDA has approved a label update for secukinumab (Cosentyx) for the treatment of moderate-to-severe scalp psoriasis, according to a Novartis press release. Scalp psoriasis affects approximately half of patients with psoriasis and is notoriously difficult to treat due to the presence of hair and other related factors.

The label will be updated in the United States immediately, according to the release.

“Scalp psoriasis is on a very sensitive, and a very visible area of the body. For patients this could translate into physical pain, frustration and social isolation,” said Kristian Reich, MD, PhD, Georg-August-University Göttingen and Dermatologikum Hamburg, Germany. “Patients and doctors are in need of effective treatment options in this and other difficult-to-treat forms of psoriasis.”

Source: Cosentyx Gains FDA Approval for Scalp Psoriasis

thumbnail courtesy of specialtypharmacytimes.com

Check out other psoriasis news here.

Additional reading: The Top 3 Psoriasis Shampoos – The Best Over the Counter Psoriasis Shampoo

About Mike Walker 28 Articles
My name is Mike Walker. I put together this blog to help others that are suffering from psoriasis. My goal is to put all of the most effective home remedies and over the counter treatments in one place.

Be the first to comment

Leave a Reply

Your email address will not be published.


*